Fintel reports that on April 10, 2023,
Morgan Stanley
maintained
coverage of Royalty Pharma (NASDAQ:RPRX) with
a Overweight recommendation.
Analyst Price Forecast Suggests 48.83% Upside
As of April 6, 2023,
the average one-year price target for Royalty Pharma is $54.04.
The forecasts range from a low of $47.47 to a high of $63.00.
The average price target represents an increase of 48.83% from its latest reported closing price of $36.31.
See our leaderboard of companies with the largest price target upside.
The projected annual revenue for Royalty Pharma
is $2,624MM, an increase of 17.30%.
The projected annual non-GAAP EPS
is $3.66.
What are Other Shareholders Doing?
CIBC Private Wealth Group
holds 12K shares
representing 0.00% ownership of the company.
No change in the last quarter.
PACK Private Wealth
holds 17K shares
representing 0.00% ownership of the company.
No change in the last quarter.
Teacher Retirement System Of Texas
holds 38K shares
representing 0.01% ownership of the company.
In it’s prior filing, the firm reported owning 72K shares, representing
a decrease
of 86.55%.
The firm
decreased
its portfolio allocation in RPRX by 99.95% over the last quarter.
LINCOLN VARIABLE INSURANCE PRODUCTS TRUST – LVIP Blended Mid Cap Managed Volatility Fund Standard Class
holds 13K shares
representing 0.00% ownership of the company.
No change in the last quarter.
Ossiam
holds 3K shares
representing 0.00% ownership of the company.
No change in the last quarter.
What is the Fund Sentiment?
There are 752 funds or institutions reporting positions in Royalty Pharma.
This is an increase
of
28
owner(s) or 3.87% in the last quarter.
Average portfolio weight of all funds dedicated to RPRX is 0.71%,
an increase
of 10.40%.
Total shares owned by institutions decreased
in the last three months by 0.25% to 344,595K shares.
The put/call ratio of RPRX is 0.19, indicating a
bullish
outlook.
Royalty Pharma Background Information
(This description is provided by the company.)
Founded in 1996, Royalty Pharma is the largest buyer of biopharmaceutical royalties and a leading funder of innovation across the biopharmaceutical industry, collaborating with innovators from academic institutions, research hospitals and not-for-profits through small and mid-cap biotechnology companies to leading global pharmaceutical companies. Royalty Pharma has assembled a portfolio of royalties which entitles it to payments based directly on the top-line sales of many of the industry’s leading therapies. Royalty Pharma funds innovation in the biopharmaceutical industry both directly and indirectly – directly when it partners with companies to co-fund late-stage clinical trials and new product launches in exchange for future royalties, and indirectly when it acquires existing royalties from the original innovators. Royalty Pharma’s current portfolio includes royalties on more than 45 commercial products, including AbbVie and J&J’s Imbruvica, Astellas and Pfizer’s Xtandi, Biogen’s Tysabri, Gilead’s HIV franchise, Merck’s Januvia, Novartis’ Promacta, and Vertex’s Kalydeco, Orkambi, Symdeko and Trikafta, and five development-stage product candidates.
See all Royalty Pharma regulatory filings.
This story originally appeared on Fintel.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
